Novartis Ag Adr (NVS)

Sep 26, 2025

Macular Edema and Macular Degeneration Market Size to Worth USD 22.51 Billion by 2034 - GlobeNewswire Inc.

Sep 26, 2025

Sep 15, 2025

Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments - Sahm

Sep 15, 2025

Sep 12, 2025

Goldman Sachs Downgrades Novartis (NVS) to Sell Over Risk Concer - GuruFocus

Sep 12, 2025

Sep 12, 2025

Novartis cut to Sell at Goldman Sachs on near-term risks (NVS:NYSE) - Seeking Alpha

Sep 12, 2025

Sep 09, 2025

Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver - sharewise.com

Sep 09, 2025

Sep 09, 2025

Novartis strikes $1.4bn deal for Tourmaline Bio - Proactive financial news

Sep 09, 2025

Sep 09, 2025

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) - Novartis

Sep 09, 2025

Sep 04, 2025

Palantir Deepens Industry Ties As Lear And Lumen Embrace Its AI Platforms - Sahm

Sep 04, 2025

Sep 03, 2025

Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.

Sep 03, 2025

Sep 03, 2025

Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases - Ariva

Sep 03, 2025

Aug 29, 2025

Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook - Sahm

Aug 29, 2025

Aug 19, 2025

Drug Delivery Devices Market To Grow At 7.90% CAGR Through 2030, Driven By FDA Approvals And Pipeline Advances By Pfizer, J&J, Novartis, Medtronic, And Becton Dickinson Through 2030 Delveinsight - Menafn

Aug 19, 2025

Aug 18, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Aug 18, 2025

Aug 17, 2025

Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm - sharewise.com

Aug 17, 2025

Aug 11, 2025

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease - Novartis

Aug 11, 2025

Aug 10, 2025

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease - Ariva

Aug 10, 2025

Aug 07, 2025

What’s Next for Pharma Stocks After Trump’s Drug Price Ultimatum? - Morningstar

Aug 07, 2025

Jul 31, 2025

Sustainable dividends from European stocks poised to benefit from the tariff wars - The Globe and Mail

Jul 31, 2025

Jul 29, 2025

INCY's Q2 Earnings & Revenues Beat Estimates On Higher Product Sales - Barchart.com

Jul 29, 2025

Jul 25, 2025

NVS’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

Jul 25, 2025

Jul 18, 2025

Novartis Holds a Strong Branded Drug Portfolio, Supporting Steady Long-Term Growth - Morningstar

Jul 18, 2025

Jul 17, 2025

Novartis Beats On Q2 Earnings And Sales, CFO Retires, Stock Down - Barchart.com

Jul 17, 2025